Day: July 17, 2024

Doctor monitoring patient healthJuly 17, 2024 Patient monitoring platform to deliver tools and time to help patients across 40+ care sites Amsterdam, the Netherlands, and Cincinnati, Ohio – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology and Bon Secours Mercy Health (BSMH), one of the nation’s largest Catholic health systems, today announced a multi-year strategic collaboration for patient monitoring. Putting BSMH clinicians in control, the collaboration will reduce the digital burden on staff and give them more time to spend with patients. The partnership provides access to the latest Philips monitoring innovations, including a scalable patient monitoring platform that integrates patient data and provides vital insights. It will standardize patient monitoring for BSMH’s 49 hospitals, reducing costs...

SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market. The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on July 31, 2024, to discuss second quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations....

Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company’s development programs, eblasakimab and farudodstatSAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (“ASLAN” or the “Company”), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that its Singapore-incorporated, sole operating subsidiary, ASLAN Pharmaceuticals Pte Ltd (“ASLAN SG”), has filed for voluntary liquidation. The decision follows a comprehensive review...

– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive interim data from the ATH434-202 open-label Phase 2 clinical trial in patients with multiple system atrophy (MSA). ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in...

Dr. Arshad Khanani to chair the newly formed Medical Advisory Board MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board (“MAB”) composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB’s role is to advise the Company on opportunities to address the unmet medical needs of patients with retinal diseases and to inform the Company’s development...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, July 17, 2024 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (“G2” or the “Company”) (TSXV:GTWO, OTCQX:GUYGF) is pleased to announce a non-brokered private placement (the “Offering”) of 28,965,365 common shares of the Company (the “Shares”) at a price of $1.45 per Share for aggregate gross proceeds of approximately C$42,000,000. The proceeds from the Offering are expected to be used to advance exploration activities at the Company’s Oko project in Guyana and for working capital and general corporate purposes. The Offering is expected to close in early August 2024 and is conditional on the satisfaction of customary conditions, including approval of the Toronto Stock Exchange. The Offering is fully subscribed. A single European investor has agreed...

Castellum, Inc. Issues Letter to ShareholdersCastellum, Inc. (the “Company” or “Castellum”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, releases this letter to shareholders from Chief Executive Officer (“CEO”), Glen Ives – http://castellumus.comVIENNA, Va., July 17, 2024 (GLOBE NEWSWIRE) — Castellum, Inc. (the “Company” or “Castellum”) (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, releases this letter to shareholders from Chief Executive Officer (“CEO”), Glen Ives. Dear Fellow Shareholders: This letter represents my first formal communication with you since I was appointed CEO by the Board...